Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age

Background. Performance of point-of-care tests in different clinical scenarios and on different samples remains undetermined. We comprehensively evaluated the performance of the nasopharyngeal Panbio COVID-19 Ag Rapid Test Device. Methods. This is a prospective study that includes consecutive patien...

Descripción completa

Detalles Bibliográficos
Autores: Masia, M, Fernandez-Gonzalez, M, Sanchez, M, Carvajal, M, Garcia, JA, Gonzalo-Jimenez, N, de la Tabla, VO, Agullo, V, Candela, I, Guijarro, J, Gutierrez, JA, de Gregorio, C, Gutierrez, F
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p11737
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/11737
Access Level:acceso abierto
Palabra clave:antigen
COVID-19
Panbio
point-of-care
SARS-CoV-2
id ES_8cccd1e6f4adffcec6eadae4c86d1a5e
oai_identifier_str oai:fisabio.fundanetsuite.com:p11737
network_acronym_str ES
network_name_str España
repository_id_str
spelling Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older AgeMasia, MFernandez-Gonzalez, MSanchez, MCarvajal, MGarcia, JAGonzalo-Jimenez, Nde la Tabla, VOAgullo, VCandela, IGuijarro, JGutierrez, JAde Gregorio, CGutierrez, FantigenCOVID-19Panbiopoint-of-careSARS-CoV-2Background. Performance of point-of-care tests in different clinical scenarios and on different samples remains undetermined. We comprehensively evaluated the performance of the nasopharyngeal Panbio COVID-19 Ag Rapid Test Device. Methods. This is a prospective study that includes consecutive patients attending 3 primary care centers (PCCs) and an emergency department. The antigen test was performed at point-of-care in nasopharyngeal and nasal swabs and in saliva. Positive percent agreement (PPA) and negative percent agreement (NPA) were calculated with the reverse-transcription polymerase chain reaction (RT-PCR) assay as reference standard. Results. Of 913 patients included, 296 (32.3%) were asymptomatic and 690 (75.6%) came from the PCC. Nasopharyngeal swabs were collected from 913 patients, nasal swabs were collected from 659 patients, and saliva was collected from 611 patients. The RT-PCR was positive in 196 (21.5%) nasopharyngeal samples (NPS). Overall, PPA (95% CI) in NPS was 60.5% (53.3-67.4), and it was lower in nasal swabs (44.7%) and saliva (23.1%). Test performance in NPS was largely dependent on the cycle threshold (Ct) in RT-PCR, with PPA of 94% for Ct <= 25 and 80% for Ct <30. In symptomatic patients, the PPA was 95% for Ct <= 25, 85% for Ct <30, and 89% for the symptom triad of fever, cough, and malaise. Performance was also dependent on age, with a PPA of 100% in symptomatic patients >50 years with Ct <25. In asymptomatic patients, the PPA was 86% for Ct <25. In all cases, NPA was 100%. Conclusions. The nasopharyngeal Panbio COVID-19 Ag test performed at point-of-care has a good sensitivity in symptomatic patients with Ct <30 and older age. The test was useful to identify asymptomatic patients with lower Ct values.OXFORD UNIV PRESS INC2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/11737Open Forum Infectious DiseasesISSN: 23288957reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p117372026-06-11T12:45:17Z
dc.title.none.fl_str_mv Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age
title Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age
spellingShingle Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age
Masia, M
antigen
COVID-19
Panbio
point-of-care
SARS-CoV-2
title_short Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age
title_full Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age
title_fullStr Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age
title_full_unstemmed Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age
title_sort Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age
dc.creator.none.fl_str_mv Masia, M
Fernandez-Gonzalez, M
Sanchez, M
Carvajal, M
Garcia, JA
Gonzalo-Jimenez, N
de la Tabla, VO
Agullo, V
Candela, I
Guijarro, J
Gutierrez, JA
de Gregorio, C
Gutierrez, F
author Masia, M
author_facet Masia, M
Fernandez-Gonzalez, M
Sanchez, M
Carvajal, M
Garcia, JA
Gonzalo-Jimenez, N
de la Tabla, VO
Agullo, V
Candela, I
Guijarro, J
Gutierrez, JA
de Gregorio, C
Gutierrez, F
author_role author
author2 Fernandez-Gonzalez, M
Sanchez, M
Carvajal, M
Garcia, JA
Gonzalo-Jimenez, N
de la Tabla, VO
Agullo, V
Candela, I
Guijarro, J
Gutierrez, JA
de Gregorio, C
Gutierrez, F
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv antigen
COVID-19
Panbio
point-of-care
SARS-CoV-2
topic antigen
COVID-19
Panbio
point-of-care
SARS-CoV-2
description Background. Performance of point-of-care tests in different clinical scenarios and on different samples remains undetermined. We comprehensively evaluated the performance of the nasopharyngeal Panbio COVID-19 Ag Rapid Test Device. Methods. This is a prospective study that includes consecutive patients attending 3 primary care centers (PCCs) and an emergency department. The antigen test was performed at point-of-care in nasopharyngeal and nasal swabs and in saliva. Positive percent agreement (PPA) and negative percent agreement (NPA) were calculated with the reverse-transcription polymerase chain reaction (RT-PCR) assay as reference standard. Results. Of 913 patients included, 296 (32.3%) were asymptomatic and 690 (75.6%) came from the PCC. Nasopharyngeal swabs were collected from 913 patients, nasal swabs were collected from 659 patients, and saliva was collected from 611 patients. The RT-PCR was positive in 196 (21.5%) nasopharyngeal samples (NPS). Overall, PPA (95% CI) in NPS was 60.5% (53.3-67.4), and it was lower in nasal swabs (44.7%) and saliva (23.1%). Test performance in NPS was largely dependent on the cycle threshold (Ct) in RT-PCR, with PPA of 94% for Ct <= 25 and 80% for Ct <30. In symptomatic patients, the PPA was 95% for Ct <= 25, 85% for Ct <30, and 89% for the symptom triad of fever, cough, and malaise. Performance was also dependent on age, with a PPA of 100% in symptomatic patients >50 years with Ct <25. In asymptomatic patients, the PPA was 86% for Ct <25. In all cases, NPA was 100%. Conclusions. The nasopharyngeal Panbio COVID-19 Ag test performed at point-of-care has a good sensitivity in symptomatic patients with Ct <30 and older age. The test was useful to identify asymptomatic patients with lower Ct values.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/11737
url https://fisabio.portalinvestigacion.com/publicaciones/11737
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv OXFORD UNIV PRESS INC
publisher.none.fl_str_mv OXFORD UNIV PRESS INC
dc.source.none.fl_str_mv Open Forum Infectious Diseases
ISSN: 23288957
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412962172665856
score 15,811543

Similares en LA Referencia